ASTRO Virtual Meeting Center

Log-in / Create Account

Session Information

2010 Multidisciplinary Head and Neck Cancer Symposium

Click here to go to the previous page

General Session VI: Personalized Cancer Therapy: Integration of Biomarkers in Clinical Trials

Track : General Sessions

Program Code: 08

Date: Friday, February 26, 2010

Time: 9:00 AM to 10:30 AM EST

Duration: 90 Minutes

Location: Akimel 3-4 Ballroom

MODERATOR:

Click the plus sign to see more detailed information about each speaker.

Gregory Wolf, M.D., FACS, Professor, University of Michigan Health System

SPEAKER(S):

Click the plus sign to see more detailed information about each speaker.

Thomas Pajak, Ph.D., Senior Statistician, Radiation Therapy Oncology Group

Thomas F. Pajak served as the RTOG Group Statistician for 23 years, from 1981 to 2004. He continues to work with RTOG investigators as a Senior Statistician. Dr. Pajak has focused on head and neck cancer clinical trials since his first day at RTOG. Dr. Pajak received his doctoral degree from the State University of New York at Buffalo. While in the program, he worked as a statistical intern in the Southwest Oncology Group (SWOG) Statistical Center at M. D. Anderson Cancer Hospital. After earning his doctorate, Dr. Pajak worked as a statistician for the Cancer and Leukemia Group B (CALGB), the Western Cancer Study Group (WCSG), and the Cancer Center at the Bowman Gray School of Medicine. In addition to his role as RTOG Senior Statistician, Dr. Pajak is an adjunct Associate Professor in the Department of Radiation Oncology at Thomas Jefferson University Hospital, and has served an editor on the American Editorial Board for International Journal of Radiation Oncology Biology Physics since 1988. Dr. Pajak serves on various Data Monitoring and Safety Boards and is an external consultant for head and neck cancer trials. He also serves as a reviewer or consultant for various National Cancer Institute committees including its current Steering Committee for Head and Neck cancer research. While his publications have encompassed the entire major adult cancers, his research interests are head and neck cancers, pathology, and tumor markers. Dr. Pajak is currently involved in analyzing retrospective HPV data from completed RTOG trials and in designing prospective clinical trials for HPV positive patients. At 2008 State of the Science symposium, Dr. Pajak discussed statistical considerations for such trials.

K. Ang, M.D., Ph.D., FASTRO, Professor, M.D. Anderson Cancer Center

Cherie-Ann Nathan, M.D., FACS, Professor, Louisiana State University Health Sciences Center - Shreveport

Professor, Vice-Chairman & Director of Head and Neck Surgical Oncology & Director of Research in the Department of Otolaryngology/HNS & the Feist-Weiller Cancer Center 2007-present and faculty for the Center for Molecular and Tumor Virology, Microbiology. Member of the previously-untreated locally advanced task force (TF) of the head and neck cancer steering committee of the National Cancer Institute (NCI) 2009. Inducted into Collegium Oto-Rhino-Laryngologicum Amicitiae Sacrum (CORLAS) 2008, and chair nominating committee for CORLAS 2009. ASCO invited program scientific committee for head and neck (2009-2012). Board of trustees for the foundation AHNS (2009). American Head and Neck Society Chairman Research Committee (2009-2012). Reviewer for Laryngoscope 2000-present. Recent publications: 1. Clark C, Ekshyyan O, Nathan CO. Effects and therapeutic potential of targeting dysregulated signaling axes in squamous cell carcinoma: AKT and MTOR in a textbook Signaling Pathways in Squamous Cancer, edited by Adam Glick (submitted). 2. Ampil F, Caldito G, Nathan CO, Ghali G, Baluna R, Jones S. Postoperative radiotherapy for head and neck cancer with single positive node. Journal of Radiotherapy in Practice, 1-5, 2009. 3. Pattani K, Goodier M, Lilien D, Kupferman T, Caldito G, Nathan CO. Utility of panendo for an unknown primary with a negative PET scan. ENT Journal, 2009 (accepted) 4. Cho A, Caldito G, Masters A, Nida A, Takalkar A, Nathan,CO. N2 disease in HNSCC patients treated with chemoradiotherapy: Is there a role for post-treatment neck dissection? Archives of Oto. 2009 (accepted) 5. Malhotra K, Morgan M, Nathan CO. Reflux as a cause of tracehoesophageal puncture failure. Laryngoscope, 119: 121-125, 2009 6. Syed Z, Cheepala SB, Gill JN, Stein J, Nathan CO, Digiovanni J, Batra V, Adegboyega P, Kleiner HE, Clifford JL. All-trans retinoic acid suppresses Stat3 signaling during skin carcinogenesis. Cancer Prev Res (Phila Pa), 2(10):903-11, 2009. 7. Ekshyyan O, Rong X, Rong Y, Pattani K, Abreo F, Caldito G, Chang J, Ampil F, Glass J, Nathan CO. Comparison of the radiosensitizing effects of the mTOR inhibitor CCI-779 to cisplatin in experimental models of HNSCC. Mol Cancer Ther. 8(8):2255-65, 2009. 8. Papadimitrakopoulou V, William W Jr., Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JJ, Du B, Yueh B, Boyle JO. Pilot randomized, Phase II study of celecoxib in oral premalignant lesion. Clinical Cancer Res, 14(7): 2095-2101, 2008. 9. Jiang R, Gu X, Nathan CO, Hutt-Fletcher L. Laser-capture microdissection of epithelial cells in the oropharynx indicates restriction of expression of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelium. Journal of Oral Pathology and Medicine; 37(10):626-33, 2008.

Audio Synchronized to PowerPoint

(Code: 08)

Member:

Members Login